Shanghai Fosun Pharmaceutical (02196): FXR0906 injection approved for clinical trials to treat hypertriglyceridemia.

Shanghai Fosun Pharmaceutical (02196) announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. (hereinafter referred to as "Shanghai Fosun Pharmaceutical (Shenzhen)"), has received approval from the National Medical Products Administration to conduct clinical trials of FXR0906 Injection for the treatment of high triglycerides. Shanghai Fosun Pharmaceutical (Shenzhen) plans to carry out Phase I clinical studies of the drug in China once conditions are met. FXR0906 is a liver-targeted siRNA drug introduced under license by the group, with exclusive rights for research, development, registration, production, and commercialization in China and Hong Kong/Macau regions. FXR0906 utilizes RNA interference technology to silence the APOC3 gene expression, reducing serum triglyceride levels and treating high triglycerides. As of June 2026, the group's cumulative research and development investment in FXR0906 is approximately RMB 71 million (including licensing fees; unaudited). As of the date of this announcement (July 15, 2026), there are no siRNA drugs approved for the treatment of high triglycerides in China.